Cargando…

SARS-CoV-2 infection: The role of PD-1/PD-L1 and CTLA-4 axis

The outbreak of SARS-CoV-2 in Wuhan of China in December 2019 and its worldwide spread has turned into the COVID-19 pandemic. Respiratory disorders, lymphopenia, cytokine cascades, and the immune responses provoked by this virus play a major and fundamental role in the severity of the symptoms and t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aghbash, Parisa Shiri, Eslami, Narges, Shamekh, Ali, Entezari-Maleki, Taher, Baghi, Hossein Bannazadeh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838580/ https://www.ncbi.nlm.nih.gov/pubmed/33508291 http://dx.doi.org/10.1016/j.lfs.2021.119124

Ejemplares similares

SARS-CoV-2: Receptor and Co-receptor Tropism Probability
por: Eslami, Narges, et al.
Publicado: (2022)

The role of antigen-presenting cells in the pathogenesis of COVID-19
por: Farzi, Rana, et al.
Publicado: (2022)

SARS-CoV-2-associated organs failure and inflammation: a focus on the role of cellular and viral microRNAs
por: Rasizadeh, Reyhaneh, et al.
Publicado: (2023)

The effect of Wnt/β-catenin signaling on PD-1/PDL-1 axis in HPV-related cervical cancer
por: AGHBASH, PARISA SHIRI, et al.
Publicado: (2023)

Dynamic alterations in white blood cell counts and SARS-CoV-2 shedding in saliva: an infection predictor parameter
por: Aghbash, Parisa Shiri, et al.
Publicado: (2023)

A comprehensive review of COVID-19 symptoms and treatments in the setting of autoimmune diseases
por: Hamidi, Zahra, et al.
Publicado: (2023)

siRNA-E6 sensitizes HPV-16-related cervical cancer through Oxaliplatin: an in vitro study on anti-cancer combination therapy
por: Shiri Aghbash, Parisa, et al.
Publicado: (2023)

Monoclonal antibodies in cervical malignancy-related HPV
por: Aghbash, Parisa Shiri, et al.
Publicado: (2022)

Spectrum and Burden of Influenza Infection: An Approach to Identify Predictors of Morbidity and Mortality Rate from the Patients of the Northwest of Iran
por: Daei Sorkhabi, Amin, et al.
Publicado: (2022)

Hepatic Disorders and COVID-19: From Pathophysiology to Treatment Strategy
por: Shiri Aghbash, Parisa, et al.
Publicado: (2022)

CRISPR–Cas system to discover host-virus interactions in Flaviviridae
por: Ramezannia, Zahra, et al.
Publicado: (2023)

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
por: Yang, Hui, et al.
Publicado: (2013)

CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma
por: Guo, Xiao-Jun, et al.
Publicado: (2021)

PD-L1/PD-1 and CTLA-4 Expression in Equine Penile Squamous Cell Carcinomas
por: Porcellato, Ilaria, et al.
Publicado: (2021)

ODP342 Panhypopituitarism Induced by CTLA-4 and PD-1/PD-L1 Inhibitor Immunotherapy
por: Hernandez-Cordero, Nicole, et al.
Publicado: (2022)

Severe acute respiratory syndrome coronavirus 2 infection: Role of interleukin-6 and the inflammatory cascade
por: Bahmani, Mohaddeseh, et al.
Publicado: (2022)

Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer
por: Quezada, S A, et al.
Publicado: (2013)

Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
por: Lee, Hyun Tae, et al.
Publicado: (2019)

Meta-Analysis of Efficacy From CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
por: Xu, Li, et al.
Publicado: (2022)

PD-L1/PD-1 Axis in Glioblastoma Multiforme
por: Litak, Jakub, et al.
Publicado: (2019)

The PD-1:PD-L1 axis in Inflammatory Arthritis
por: Canavan, Mary, et al.
Publicado: (2021)

PD-1/PD-L1 axis in organ fibrosis
por: Zhao, Youliang, et al.
Publicado: (2023)

Expression of PD‐L1 and CTLA‐4 in female urethral carcinoma
por: Ninomiya, Sahoko, et al.
Publicado: (2018)

Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment
por: Tunger, Antje, et al.
Publicado: (2018)

Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4
por: Pandey, Pratibha, et al.
Publicado: (2022)

Targeting the PD-1/PD-L1 Axis in Human Vitiligo
por: Willemsen, Marcella, et al.
Publicado: (2020)

Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis
por: Krutzek, Fabian, et al.
Publicado: (2022)

Role of the PD-1 and PD-L1 axis in COVID-19
por: R Bonam, Srinivasa, et al.
Publicado: (2022)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
por: Long, Yiru, et al.
Publicado: (2022)

PD-1/PD-L Axis in Neuroinflammation: New Insights
por: Manenti, Susanna, et al.
Publicado: (2022)

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
por: Callahan, Margaret K., et al.
Publicado: (2015)

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
por: Heinzerling, Lucie, et al.
Publicado: (2016)

Combination of CTLA-4 and PD-1 blockers for treatment of cancer
por: Rotte, Anand
Publicado: (2019)

Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1
por: Hao, Yuwei, et al.
Publicado: (2022)

Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?
por: Feng, Yuqian, et al.
Publicado: (2021)

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
por: Zhang, Hao, et al.
Publicado: (2021)

Enoxaparin’s potential mechanisms against SARS-CoV-2
por: Afsharirad, Bentelhoda, et al.
Publicado: (2023)

The PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity in Cancer
por: Yajuk, Olga, et al.
Publicado: (2021)

Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis
por: Huang, Shuang, et al.
Publicado: (2023)

Commentary on ‘Implications of the SARS-CoV-2 subvariants BA.4 and BA.5’
por: Khani, Elnaz, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5r9mgd7tib8g4t71uhm7kkjppr